Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29136631 | 0.85 | CYP11B1 (0.53) | CYP11B1CYP11B2LMNACPB2ALDH1A1 | |
| SCHEMBL27744671 | 0.84 | KLKB1 (0.41) | CYP11B1CYP11B2CPB2KLKB1 | |
| SCHEMBL21199434 | 0.82 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP19A1LMNACPB2 | |
| SCHEMBL2972635 | 0.81 | HPGDS (0.51) | CYP11B1CYP11B2CYP19A1CPB2MAPT | |
| SCHEMBL2979842 | 0.81 | CDK5 (0.50) | CYP11B1CYP19A1MAPTMEN1KMT2A | |
| SCHEMBL18961343 | 0.80 | CYP11B1 (0.55) | CYP11B1CYP11B2LMNAMEN1KMT2A | |
| SCHEMBL15965385 | 0.76 | KLKB1 (0.49) | CYP11B1CYP11B2CYP19A1KLKB1 | |
| SCHEMBL4837186 | 0.75 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP19A1LMNACPB2 | |
| SCHEMBL21533373 | 0.75 | ALDH1A1 (0.42) | CYP11B1CYP11B2CYP19A1HTTKLKB1 | |
| SCHEMBL20344417 | 0.75 | CYP11B1 (0.46) | CYP11B1CYP11B2CYP19A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC | 2007-03-22 | — | — | US | claimed |
| US-7781435-B2 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100184737-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PFIZER INC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | APP, PSEN1, BACE1 | CYP11B1 295/4885CYP11B2 439/4885CYP19A1 1110/4885 |
| US-20100184737-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | APP, PSEN1, BACE1 | CYP11B1 295/4885CYP11B2 439/4885CYP19A1 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.